What's Happening?
The U.S. Food and Drug Administration (FDA) has approved the combination of Inqovi (decitabine and cedazuridine) with venetoclax as the first all-oral treatment regimen for adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older
or ineligible for intensive induction chemotherapy. This approval is based on the Phase 2 ASCERTAIN-V study, which demonstrated a complete remission rate of 41.6% with the combination therapy. Inqovi was previously approved for myelodysplastic syndromes and chronic myelomonocytic leukemia.
Why It's Important?
This approval provides a significant advancement in the treatment of AML, particularly for older patients or those unable to undergo intensive chemotherapy. The all-oral regimen offers a more convenient and less invasive treatment option, potentially improving patient compliance and quality of life. This development highlights the ongoing innovation in cancer treatment, focusing on patient-centered approaches that reduce the burden of frequent clinic visits and invasive procedures.
What's Next?
With the approval of this new regimen, healthcare providers will need to integrate it into treatment plans for eligible AML patients. The success of this combination therapy could lead to further research into oral regimens for other cancer types, potentially expanding treatment options for patients with limited therapeutic choices. Additionally, Taiho Oncology may explore further applications of Inqovi in combination with other therapies, enhancing its oncology portfolio.
